CA-NETAPP,-INC.
8.6.2021 14:02:09 CEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP) a global, cloud-led, data-centric software company, today unveiled a new release of its ONTAP software that powers data services on premises and in the cloud, as well as an array of portfolio updates that leverage ONTAP to provide a flexible foundation for hybrid cloud, unify data management across on-premises and cloud environments, and simplify consumption and operation of hybrid cloud services. As the only provider of hybrid cloud solutions that offers native integration with the world’s leading public clouds, NetApp is unifying management of on-premises and public cloud environments, delivering new ways to consume and operate data services that make it easier for enterprises to put their data to work – wherever and whenever they need it.
The latest enhancements to NetApp’s hybrid cloud portfolio and ONTAP data services include:
-
Flexible Foundations for Hybrid Cloud
Enterprises need to modernize their IT environments to enable hybrid cloud operations. NetApp is updating its foundational solutions to better support them:
-
FlexPod:
The next generation of the globally trusted converged infrastructure platform from NetApp and Cisco provides a better foundation for hybrid cloud with the flexibility to run and manage all your modern workloads. New capabilities include intelligent application placement across on-premises and cloud, automated hybrid cloud data workflows, and the ability to consume FlexPod as a fully managed, cloud-like service.
- NetApp StorageGRID: The 11.5 release of NetApp’s highly scalable object store now supports data encryption using external key management, offers compliance and ransomware protection with S3 object locks, and delivers increased performance with intelligent load balancing.
-
FlexPod:
The next generation of the globally trusted converged infrastructure platform from NetApp and Cisco provides a better foundation for hybrid cloud with the flexibility to run and manage all your modern workloads. New capabilities include intelligent application placement across on-premises and cloud, automated hybrid cloud data workflows, and the ability to consume FlexPod as a fully managed, cloud-like service.
-
Simple, Unified Data Management Across Hybrid Cloud Environments
Managing data and applications in hybrid cloud environments can be extremely challenging – enterprises need a simple, standardized approach. NetApp centralizes data management across the hybrid cloud to make things simpler. NetApp Cloud Manager and enhanced multicloud management services automate ONTAP data services to simplify application migration, disaster recovery, data protection, governance and compliance. In addition, NetApp Astra, an application-aware data service for Kubernetes, enables customers to manage, protect, and migrate stateful applications in Google Cloud, Microsoft Azure – and now on-premises.
-
Cloud-Like Financial Flexibility and Operational Simplicity
Organizations want the same financial and operational elasticity they get from the cloud in their data center, with the freedom to move and manage workloads easily and securely across hybrid and public cloud environments. The new NetApp Keystone Flex Subscription at Equinix gives customers the ability to deploy Keystone data services in Equinix International Business Exchange™ (IBX®) for low-latency access to multiple clouds – without having to move their data to the cloud. The Keystone Flex Subscription at Equinix is uniquely delivered as a single subscription by NetApp.
“NetApp’s Keystone Flex Subscription at Equinix uniquely provides a flexible, on-demand storage alternative to traditional capex infrastructure investments,” said Royce Thomas, senior vice president, strategic alliances and global account management at Equinix. “With this offering, global businesses can host their data adjacent to the cloud and utilize Equinix Fabric™ to connect to service providers, taking advantage of centralized hybrid cloud data management across all major public clouds.”
“A hybrid cloud strategy is critical to ensuring organizations can keep pace with the growth and complexity of distributed data and applications, thrive in the face of uncertainty and compete effectively in the digital economy,” said Kim Stevenson, senior vice president and general manager, foundational data services business unit at NetApp. “NetApp specializes in helping enterprises at every phase in their digital transformation journeys to implement hybrid cloud strategies and technologies that will help keep them ahead of the curve.”
Additional Resources
- NetApp hybrid cloud portfolio: https://www.netapp.com/hybrid-cloud/
- Latest release of ONTAP: read the blog , visit the solution page
- Latest release of NetApp Astra Control: read the blog , visit the solution page
- NetApp Keystone Flex Subscription with Equinix: read the blog , read the solution brief
- Next generation FlexPod: read the blog , visit the solution page
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloud-like experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005287/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
